赖氨酸氧化酶抑制剂在结直肠癌进展中的作用。

IF 4.5 2区医学 Q1 ONCOLOGY

Translational Oncology Pub Date : 2025-02-01 Epub Date: 2024-12-15 DOI:10.1016/j.tranon.2024.102233

Muxian Liu, Jie Wang, Meihong Liu

{"title":"赖氨酸氧化酶抑制剂在结直肠癌进展中的作用。","authors":"Muxian Liu, Jie Wang, Meihong Liu","doi":"10.1016/j.tranon.2024.102233","DOIUrl":null,"url":null,"abstract":"The lysine oxidase (LOX) family, consisting of LOX and LOX-like-1-4 (LOXL1-LOXL4), catalyses the cross-linking reaction of collagen and elastin in the extracellular matrix (ECM). Numerous studies have demonstrated that LOX family members are dysregulated in a variety of cancers, including colorectal cancer (CRC), and play a key role in cancer cell migration, proliferation, invasion and metastasis. Targeting LOX family proteins with specific inhibitors has therefore been developed as a new therapeutic strategy for cancer. In this paper, we review the role of LOX enzymes in the development and progression of CRC. In addition, we address recent advances in the development of LOX/LOXL inhibitors, highlighting the potential use of this inhibitor as an effective and complementary treatment for CRC.","PeriodicalId":23244,"journal":{"name":"Translational Oncology","volume":"52 ","pages":"102233"},"PeriodicalIF":4.5000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11713484/pdf/","citationCount":"0","resultStr":"{\"title\":\"Lysyl oxidase inhibitors in colorectal cancer progression.\",\"authors\":\"Muxian Liu, Jie Wang, Meihong Liu\",\"doi\":\"10.1016/j.tranon.2024.102233\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The lysine oxidase (LOX) family, consisting of LOX and LOX-like-1-4 (LOXL1-LOXL4), catalyses the cross-linking reaction of collagen and elastin in the extracellular matrix (ECM). Numerous studies have demonstrated that LOX family members are dysregulated in a variety of cancers, including colorectal cancer (CRC), and play a key role in cancer cell migration, proliferation, invasion and metastasis. Targeting LOX family proteins with specific inhibitors has therefore been developed as a new therapeutic strategy for cancer. In this paper, we review the role of LOX enzymes in the development and progression of CRC. In addition, we address recent advances in the development of LOX/LOXL inhibitors, highlighting the potential use of this inhibitor as an effective and complementary treatment for CRC.\",\"PeriodicalId\":23244,\"journal\":{\"name\":\"Translational Oncology\",\"volume\":\"52 \",\"pages\":\"102233\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11713484/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.tranon.2024.102233\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/15 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.tranon.2024.102233","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/15 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

赖氨酸氧化酶（LOX）家族由LOX和LOX样-1-4 （LOXL1-LOXL4）组成，在细胞外基质（ECM）中催化胶原和弹性蛋白的交联反应。大量研究表明，LOX家族成员在包括结直肠癌（CRC）在内的多种癌症中都存在异常，并在癌细胞迁移、增殖、侵袭和转移中发挥关键作用。因此，利用特异性抑制剂靶向LOX家族蛋白已成为一种新的癌症治疗策略。本文就LOX酶在结直肠癌发生发展中的作用作一综述。此外，我们讨论了LOX/LOXL抑制剂的最新进展，强调了该抑制剂作为结直肠癌有效和补充治疗的潜在用途。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Lysyl oxidase inhibitors in colorectal cancer progression.

The lysine oxidase (LOX) family, consisting of LOX and LOX-like-1-4 (LOXL1-LOXL4), catalyses the cross-linking reaction of collagen and elastin in the extracellular matrix (ECM). Numerous studies have demonstrated that LOX family members are dysregulated in a variety of cancers, including colorectal cancer (CRC), and play a key role in cancer cell migration, proliferation, invasion and metastasis. Targeting LOX family proteins with specific inhibitors has therefore been developed as a new therapeutic strategy for cancer. In this paper, we review the role of LOX enzymes in the development and progression of CRC. In addition, we address recent advances in the development of LOX/LOXL inhibitors, highlighting the potential use of this inhibitor as an effective and complementary treatment for CRC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Translational Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

7.20

自引率

2.00%

发文量

314

审稿时长

6-12 weeks

期刊介绍： Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.